MY148589A - Neurotherapeutic azole compounds - Google Patents
Neurotherapeutic azole compoundsInfo
- Publication number
- MY148589A MY148589A MYPI20061865A MYPI20061865A MY148589A MY 148589 A MY148589 A MY 148589A MY PI20061865 A MYPI20061865 A MY PI20061865A MY PI20061865 A MYPI20061865 A MY PI20061865A MY 148589 A MY148589 A MY 148589A
- Authority
- MY
- Malaysia
- Prior art keywords
- azole compounds
- stroke
- neurotherapeutic
- compounds
- adhd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67453005P | 2005-04-22 | 2005-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY148589A true MY148589A (en) | 2013-05-15 |
Family
ID=37115369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20061865A MY148589A (en) | 2005-04-22 | 2006-04-24 | Neurotherapeutic azole compounds |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7598279B2 (enExample) |
| EP (1) | EP1879873B1 (enExample) |
| JP (1) | JP5035238B2 (enExample) |
| KR (1) | KR101286499B1 (enExample) |
| CN (1) | CN101228138B (enExample) |
| AR (1) | AR053065A1 (enExample) |
| AU (1) | AU2006237798B2 (enExample) |
| BE (1) | BE2021C524I2 (enExample) |
| BR (1) | BRPI0607529B8 (enExample) |
| CA (1) | CA2606258C (enExample) |
| DK (1) | DK1879873T3 (enExample) |
| ES (1) | ES2441765T3 (enExample) |
| FI (1) | FIC20210018I1 (enExample) |
| MX (1) | MX2007013197A (enExample) |
| MY (1) | MY148589A (enExample) |
| NL (1) | NL301106I2 (enExample) |
| PL (1) | PL1879873T3 (enExample) |
| PT (1) | PT1879873E (enExample) |
| RU (1) | RU2418792C2 (enExample) |
| TW (1) | TWI398249B (enExample) |
| WO (1) | WO2006112685A1 (enExample) |
| ZA (1) | ZA200709994B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| EP2155736B1 (en) * | 2007-05-14 | 2011-12-21 | SK Holdings Co., Ltd. | Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound |
| AU2008258599B2 (en) | 2007-06-05 | 2013-06-13 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| WO2009148290A2 (en) * | 2008-06-05 | 2009-12-10 | Sk Holdings Co., Ltd. | 3-substituted propanamine compounds |
| WO2010150946A1 (en) * | 2009-06-22 | 2010-12-29 | Sk Holdings Co., Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| RU2557533C2 (ru) | 2009-11-06 | 2015-07-20 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома фибромиалгии |
| CA2779457C (en) | 2009-11-06 | 2017-10-17 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| AU2013202982C1 (en) * | 2012-01-06 | 2017-01-05 | Novartis Ag | Heterocyclic compounds and methods for their use |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| TWI655179B (zh) * | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102901908B1 (ko) * | 2016-12-14 | 2025-12-17 | 에스케이바이오팜 주식회사 | 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| US11147798B2 (en) | 2016-12-14 | 2021-10-19 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| KR102900173B1 (ko) * | 2016-12-14 | 2025-12-12 | 에스케이바이오팜 주식회사 | 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도 |
| KR102635931B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| WO2018111008A1 (ko) * | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| EP3556345B1 (en) | 2016-12-14 | 2021-09-22 | SK Biopharmaceuticals Co., Ltd. | Orally disintegrated tablet comprising carbamate compound |
| AU2017374450B2 (en) * | 2016-12-14 | 2023-05-11 | Sk Biopharmaceuticals Co., Ltd. | Parenteral liquid preparation comprising carbamate compound |
| CN110267657B (zh) * | 2016-12-14 | 2022-12-13 | 爱思开生物制药株式会社 | 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途 |
| WO2019098632A1 (ko) | 2017-11-14 | 2019-05-23 | 에스케이바이오팜 주식회사 | 근긴장증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| ES3027977T3 (en) * | 2017-11-14 | 2025-06-17 | Sk Biopharmaceuticals Co Ltd | Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease |
| IL274437B2 (en) * | 2017-11-14 | 2024-09-01 | Sk Biopharmaceuticals Co Ltd | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
| WO2019098630A1 (ko) | 2017-11-14 | 2019-05-23 | 에스케이바이오팜 주식회사 | 취약 x 증후군, 엔젤만 증후군 또는 렛 증후군을 포함하는 발달 장애의 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| EP3711758B1 (en) * | 2017-11-14 | 2024-03-27 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure |
| ES2973111T3 (es) * | 2017-11-14 | 2024-06-18 | Sk Biopharmaceuticals Co Ltd | Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio |
| BR112021005193A2 (pt) * | 2018-09-21 | 2021-06-08 | Sk Biopharmaceuticals Co., Ltd. | medicamento e combinação para a prevenção, alívio ou tratamento de transtorno de estresse agudo ou transtorno de estresse pós-traumático, e, medicamento para a prevenção, alívio ou tratamento de sintoma de transtorno de estresse pós-traumático |
| TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| KR20210047887A (ko) * | 2018-09-21 | 2021-04-30 | 에스케이바이오팜 주식회사 | 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도 |
| WO2020080866A1 (ko) | 2018-10-19 | 2020-04-23 | 에스케이바이오팜 주식회사 | 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도 |
| US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
| EP4062906A4 (en) * | 2019-11-22 | 2024-01-03 | SK Biopharmaceuticals Co., Ltd. | ORAL PHARMACEUTICAL COMPOSITION COMPRISING A CARBAMAT COMPOUND AND PROCESS FOR PRODUCTION THEREOF |
| BR112023002056A2 (pt) | 2020-08-06 | 2023-03-07 | Sk Biopharmaceuticals Co Ltd | Forma de dosagem oral sólida, e, método para preparar uma forma de dosagem oral sólida |
| CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
| AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
| ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
| CN115716810A (zh) * | 2022-11-15 | 2023-02-28 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
| CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) * | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DK181988A (da) * | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
| ATE144501T1 (de) * | 1991-08-22 | 1996-11-15 | Warner Lambert Co | Tetrazolamide als acat inhibitoren |
| ES2294140T3 (es) * | 2001-06-25 | 2008-04-01 | Sk Holdings Co Ltd. | Carbamatos de 2-heterociclico-1,2-etanodioles. |
| US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko active Active
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en active Active
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es active Active
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh active Active
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja active Active
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 CA CA2606258A patent/CA2606258C/en active Active
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en active Active
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en not_active Ceased
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
- 2021-06-28 BE BE2021C524C patent/BE2021C524I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY148589A (en) | Neurotherapeutic azole compounds | |
| EP1778341A4 (en) | DYNAMIC NERVE STIMULATION FOR THE TREATMENT OF DISEASES | |
| MX2011001384A (es) | Composiciones y metodos para tratar trastornos psiquiatricos. | |
| EP1786515A4 (en) | TREATMENT OF THE VEGETABLE NERVOUS SYSTEM | |
| TW200510324A (en) | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist | |
| WO2007025286A3 (en) | Therapy procedure for drug delivery for trigeminal pain | |
| EP2532657A3 (en) | Compounds and methods of use | |
| WO2004041258A3 (fr) | Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie | |
| IL183673A0 (en) | Apparatus and method for the conditioning of muscular fibrils reaction coordination capacity by means of biomechanical stimulation | |
| IL190080A0 (en) | Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate trasmembrane drug delivery into the middle ear | |
| MA33241B1 (fr) | Composes pour le traitement de troubles metaboliques | |
| EP2086478A4 (en) | DYNAMIC MULDE, ESPECIALLY FOR THE TREATMENT OF HEAD AND NECK PAIN | |
| EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
| IL184578A0 (en) | Method and composition for treating central nervous system disorders | |
| WO2005099702A3 (en) | R(-)-11-hydroxyaporphine derivatives and uses thereof | |
| WO2007109288A3 (en) | Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use | |
| IL190831A0 (en) | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion | |
| UA97401C2 (ru) | Экструдат с улучшенной маскировкой вкуса | |
| NZ548926A (en) | Inhibitors of TGF-R signaling for treatment of CNS disorders | |
| NZ606276A (en) | Fastening Means | |
| EP1961447A3 (en) | Treating depressive disorders with PKC activators | |
| WO2006023452A3 (en) | Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases | |
| PT1853232E (pt) | Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização | |
| EP1551397A4 (en) | GUANIDINE COMPOUNDS AS A NARCOSANT AND FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | |
| ZA200607641B (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |